# Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients

> **NCT02471820** · PHASE2 · COMPLETED · sponsor: **Meletios A. Dimopoulos** · enrollment: 45 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Adriamycin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02471820
- **Lead sponsor:** Meletios A. Dimopoulos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471820, "Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02471820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*